SCHEMBL30765840

SCHEMBL30765840

O=C(Cn1c(N2CCOCC2)cnc(NC(=O)c2coc(-c3ccccc3)n2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.38
IRAK4 Q9NWZ3 4/20 0.37
DGAT2 Q96PD7 1/20 0.35
MAPK1 P28482 1/20 0.35
NTRK1 P04629 2/20 0.35
KCNH2 Q12809 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
CYP3A4 P08684 2/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
CCNK O75909 1/20 0.34
CDK12 Q9NYV4 1/20 0.34
F2 P00734 1/20 0.34
F7 P08709 1/20 0.34
F3 P13726 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765816 0.83 NTRK1 (0.38) NAMPTIRAK4DGAT2NTRK1POLB
SCHEMBL30765627 0.80 DGAT2 (0.39) IRAK4DGAT2MAPK1NTRK1F2
SCHEMBL30765443 0.78 ELANE (0.39) IRAK4DGAT2NTRK1F2F3
SCHEMBL30765657 0.76 F2 (0.36) NAMPTMAPK1NTRK1CYP3A4PIK3CD
SCHEMBL30765889 0.76 ELANE (0.38) DGAT2NTRK1F3NTRK3
SCHEMBL30765780 0.76 NAMPT (0.40) NAMPTMAPK1NTRK1CYP2C9CCNK
SCHEMBL30765728 0.74 MAPK1 (0.38) NAMPTMAPK1CCNKCDK12F2
SCHEMBL30765466 0.74 DGAT2 (0.47) DGAT2F3
SCHEMBL23474447 0.71 NTRK1 (0.48) NTRK1F2F7F3NTRK3
SCHEMBL31751198 0.71 MAPK1 (0.36) NAMPTMAPK1NTRK1CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed